The invention aims to provide an avian influenza virus vaccine. According to the avian influenza virus vaccine, antigen is inactivated H9 subtype avian influenza virus, and has a preservation number of CCTCC No. V201617. The new H9 subtype avian influenza virus strain FJ 11 used in the vaccine is high in titer of HA and EID<50> (egg infectious dose), good in immunogenicity, and can withstand attacks of local epidemic isolated virus of the H9 subtype avian influenza virus. The prepared vaccine by the invention is good in safety, and is free of any local or systemic adverse reactions caused by the vaccine. In the preservation period test, analysis of data of shape and properties, a safety test and a potency test is performed, the results show that all indexes are stable and effective compared with similar products; the potency test shows that the H9 subtype avian influenza inactivated vaccine antibody is quicker in production than the similar products, most importantly, protection of epidemic strains can be withstood after immunization.